Lung cancer: a cost and outcome study based on physician practice patterns.
Chemotherapy is now an acceptable treatment for selected patients with non-small-cell lung cancer. With the wide assortment of cytotoxic and supportive-care drugs, there are opportunities for assessing the value of various treatment approaches. This study was undertaken to assess variations in treatment patterns in a large oncology group with emphasis on costs incurred and survival. A total of 1215 patients seen in 1996 by Medical Oncologists (a community-based private practice) were identified as new lung cancer patients by review of billing data. Of these, 858 received chemotherapy and were evaluated for charges. Three hundred were evaluated for charges, hospice care, and survival. Differences in practice patterns for physicians and the causes of those differences were assessed. Differences in survival, charges, and hospice care for those patients who were seen by high-charge and low-charge physicians were measured. Clear differences emerged in practice patterns for these Medical Oncologists. Higher charges were associated with higher average number of chemotherapy cycles given, greater use of second- and third-line chemotherapy and greater use of support drugs, particularly G-CSF and erythropoietin. For stage IV non-small-cell lung cancer, there was no difference in survival or in hospice utilization for the two groups. For all patients combined, there was no significant survival difference. There may be as much as 100% difference in costs incurred for lung cancer chemotherapy based on variations in practice patterns alone without a measurable survival difference. These results suggest approaches for cost-minimization and disease management. These suggestions have been reinforced by recent clinical data and guideline development.
Hoverman
J Russell
JR
Clinical Resource Management Department, Texas Oncology P A, Dallas, Texas 75251, USA. russell.hoverman@usoncology.com
Robertson
S Marciann
SM
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000191:economics*; D003365:Costs and Cost Analysis; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000191:economics*; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D010818:Practice Patterns, Physicians'; D015996:Survival Rate; D013781:Texas
D000970:Antineoplastic Agents